Brief: Enanta Pharmaceuticals Announces Positive Phase 2 Results Evaluating Zelicapavir
09/12/2024 12:00
Dec 9 (Reuters) - Enanta Pharmaceuticals Inc ENTA.O :
* ENANTA PHARMACEUTICALS ANNOUNCES POSITIVE TOPLINE RESULTS
FROM
FIRST-IN-PEDIATRICS PHASE 2 STUDY EVALUATING ZELICAPAVIR FOR THE
TREATMENT OF RESPIRATORY SYNCYTIAL VIRUS (RSV)
* ENANTA PHARMACEUTICALS INC - ANTIVIRAL EFFECT OBSERVED
WITH 1.4
LOG VIRAL LOAD DECLINE IN PART 2
* ENANTA PHARMACEUTICALS INC - ZELICAPAVIR WELL-TOLERATED
WITH
FAVORABLE SAFETY PROFILE
Source text: ID:nBw89P9ZQa
Further company coverage: ENTA.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Enanta Pharmaceuticals
See all newsEnanta Pharmaceuticals Inc reports results for the quarter ended June 30 - Earnings Summary
Enanta Pharmaceuticals Q3 revenue misses estimates, hurt by lower royalties
Enanta Pharmaceuticals Inc expected to post a loss of 51 cents a share - Earnings Preview
Enanta Pharma Q2 loss narrows on higher AbbVie royalties, lower costs
Enanta Pharmaceuticals Q1 revenue beats estimates